Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Gastric AdenocarcinomaGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaPeritoneal Metastasis
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06914687
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
Phase 4
Not yet recruiting
- Conditions
- Pancreatic CancerMaintenance TherapyPostoperative Adjuvant Therapy
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 464
- Registration Number
- NCT06779318
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Phase 2
Not yet recruiting
- Conditions
- Gastric CancerHER2 + Gastric CancerPD-L1 PositiveCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 140
- Registration Number
- NCT06881017
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients with Locally Advanced Gastric Cancer
Phase 1
Not yet recruiting
- Conditions
- Stomach NeoplasmGastric (Stomach) Cancer
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 57
- Registration Number
- NCT06732856
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2
Recruiting
- Conditions
- HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric Carcinoma
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
Shandong Univerisity Qilu Hospital, Jinan, Shandong, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Jinan Third People's Hospital, Jinan, Shandong, China
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2
Recruiting
- Conditions
- Recurrent or Metastatic Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 56
- Registration Number
- NCT06657690
- Locations
- 🇨🇳
Fifth affiliated hosptial of Sun-yat Sen university, Zhuhai, Guangzhou, China
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Unresectable Esophageal Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06598917
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 40
- Registration Number
- NCT06555471
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Phase 2
- Conditions
- Gastric Cancer Peritoneal Metastases
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 42
- Registration Number
- NCT06487715
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath